Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Expanded Access Program of Surufatinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04814732
Expanded Access Status : Available
First Posted : March 24, 2021
Last Update Posted : April 13, 2022
Information provided by (Responsible Party):
Hutchison Medipharma Limited

Brief Summary:
This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Condition or disease Intervention/treatment
Neuroendocrine Tumors Drug: Surufatinib

Detailed Description:

Prior to any assessments, all subjects must provide a signed ICF. Prior to inclusion in the program, the patients must undergo all appropriate screening procedures to check for eligibility.

Once eligibility is confirmed, patients will receive treatment with surufatinib 300mg, orally (PO), daily (QD). All patients will undergo continuous monitoring for safety until the end of treatment.

There is no pre-defined duration of treatment for each patient. Patients will be treated until progressive disease (as defined by treating physician), unacceptable toxicity, death, withdrawal from program, the treatment becomes commercially available, or halting of product development.

A follow-up clinic visit is recommended for all patients approximately 30 days after last dose of treatment to complete the final safety assessments, as applicable.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients, Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors

Intervention Details:
  • Drug: Surufatinib

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Histologically or cytologically documented, well differentiated, locally advanced or metastatic NETs
  2. The patient or parent/legal guardian (as appropriate) is willing and able to provide informed consent, and where required, the patient is willing to provide assent
  3. ≥12 years of age
  4. In the opinion of the patient's treating physician, other treatment options or clinical trials in this indication are unsuitable
  5. Patient has adequate bone marrow and organ function
  6. Urine dipstick ≤1+ for proteinuria or ≤30 mg/dL in urinalysis,
  7. ECOG ≤2 for adult patients (≥18 years of age), Karnofsky ≥60 for patients >16 and <18 years of age, and Lansky ≥60 for pediatric patients ≤16 years of age
  8. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and partner) to use a highly effective form(s) of contraception

Exclusion Criteria:

  1. Uncontrollable hypertension, as defined by local institution
  2. Gastrointestinal disease or condition that the physician suspects may affect drug absorption
  3. History or presence of a serious hemorrhage
  4. Clinically significant cardiovascular disease
  5. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy
  6. High risk of bleeding at screening due to tumor invasion
  7. Arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing or thromboembolic events (including stroke and/or transient ischemic attack) within 6 months prior to first dosing
  8. Received treatment with anticancer therapy, including investigational therapy, within 7 days or 5 half-lives (whichever is longer)
  9. Received prior treatment with surufatinib
  10. Inability to take medication orally
  11. Any other clinically significant comorbidities that, in the judgment of the treating physician, could predispose the patient to safety risks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04814732

Layout table for location contacts
Contact: Leslie Callahan, BSN,MS +1 973-826-5578
Contact: John Kauh

Layout table for location information
United States, Colorado
Rocky Mountain Cancer Center Available
Denver, Colorado, United States, 80218
Contact: Jennifer Hege    303-385-2067   
Principal Investigator: Allen L Cohn, MD         
United States, Maryland
Mercy Medical Center, Medical Oncology & Hematology Available
Baltimore, Maryland, United States, 21202
Contact: Alexandra Cline    410-951-7956   
Principal Investigator: Sandy D Kotiah, MD         
United States, Michigan
Karmanos Cancer Center Available
Detroit, Michigan, United States, 48201
Contact: Taylor Brewer, CCRP    313-576-8526   
Principal Investigator: Mohammed Al Hallak, MD         
United States, Missouri
MidAmerica Cancer Care Available
Kansas City, Missouri, United States, 64114
Contact: Jennifer Ross    660-383-3197   
Principal Investigator: Jaswinder Singh, MD         
United States, New Jersey
Summit Medical Group Available
Florham Park, New Jersey, United States, 07932
Contact: Michelle MacKenzie    973-538-5210   
Principal Investigator: David Gallison, DO         
United States, New York
Roswell Park Cancer Institute Available
Buffalo, New York, United States, 14263
Contact: Roswell Park    800-767-9455   
Principal Investigator: Renuka Iyer, MD         
United States, Oregon
Providence Cancer Institute Franz Clinic, Providence Health & Services Available
Portland, Oregon, United States, 97213
Contact: Katrina Herz    503-215-2617   
Contact: Lena Yamasaki   
Principal Investigator: Hagaan F. Kennecke, MD         
United States, South Dakota
Avera Cancer Institute Available
Sioux Falls, South Dakota, United States, 57105
Contact: Heidi Nickles    605-322-3295   
Principal Investigator: Heidi McKean, MD         
United States, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center Available
Dallas, Texas, United States, 75246
Contact: Jonathan Huntzinger    214-370-1942   
Principal Investigator: Andrew S Paulson, MD         
United States, Utah
Intermountain Healthcare Available
Murray, Utah, United States, 84107
Contact: Tracy Taylor    801-507-3953   
Principal Investigator: Mark A Lewis, MD         
Intermountain Cancer Center Available
Saint George, Utah, United States, 84790
Contact: Emily Lowe    435-251-4746   
Principal Investigator: Ryan Wilcox, MD         
Sponsors and Collaborators
Hutchison Medipharma Limited
Layout table for investigator information
Study Chair: John Kauh, MD Hutchison Medipharma Limited
Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited Identifier: NCT04814732    
Other Study ID Numbers: 2020-012-GLOB3
First Posted: March 24, 2021    Key Record Dates
Last Update Posted: April 13, 2022
Last Verified: April 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue